Negotiable: Proclinical Staffing: Proclinical are working with a Biotechnology Company to recruit for an experience individual for the role of HR...
Vous n'êtes pas connecté
US patent includes broad claims for treating brain neurological disorders CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announces the expansion of protection for potential clinical indications for its EB-002 drug candidate through the issuance […]
Negotiable: Proclinical Staffing: Proclinical are working with a Biotechnology Company to recruit for an experience individual for the role of HR...
RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.
RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
New research from the University of Kentucky’s Sanders-Brown Center on Aging has revealed that the cognitive impairments seen in long COVID patients...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....
In the complex landscape of mental health research, a new peer-reviewed Viewpoint review sheds light on an underexplored genetic player: the trace...
KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista...
BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval...
BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval...